title: The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.
abstract: A high negative-predictive value of (18)F-fluorodeoxyglucose (FDG) PET in early and late response assessment of Hodgkin's lymphoma patients has been observed in numerous trials. The consequent substantial reduction in the number of chemotherapy cycles and radiotherapy in many current trials seems to be very promising. The criteria used to describe (18)F-FDG accumulation are widely standardized, but PET interpretation in a dedicated clinical algorithm is being discussed among study groups and will be evaluated in the ongoing trials. The integration of (18)F-FDG PET into radiation treatment planning could have a substantial impact on treatment volumes within the new target definition 'involved-node radiotherapy'. Involved-node radiotherapy has been proposed as a means to further improve the therapeutic ratio by reducing the risk of acute radiation-induced toxicity and potentially lowering the rate of long-term complications, including secondary malignancies.
authors.affiliation: Department of Nuclear Medicine, University Hospital of Cologne, Germany. carsten.kobe@uk-koeln.de
authors.forename: Carsten
authors.initials: C
authors.lastname: Kobe
authors.forename: Markus
authors.initials: M
authors.lastname: Dietlein
authors.forename: Jan
authors.initials: J
authors.lastname: Kriz
authors.forename: Christian
authors.initials: C
authors.lastname: Furth
authors.forename: Michael
authors.initials: M
authors.lastname: Fuchs
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Hans Theodor
authors.initials: HT
authors.lastname: Eich
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals
chemical_list: D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18